Quantcast

Latest Prostate cancer Stories

2014-07-16 08:28:30

DCVax®-Direct Phase II Trial Preparations and Manufacturing Expansion Underway BETHESDA, Md., July 16, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that the Phase I portion of the Company's Phase I/II DCVax-Direct clinical trial has completed its 36-patient target recruitment, and the Company is now underway with preparations for the Phase II...

2014-07-16 04:21:39

TUEBINGEN, Germany, July 16, 2014 /PRNewswire/ -- Funds will be used to complete phase 3 study with IMA901 and to invest in the expansion of immatics' Human Immunopeptidome Program to identify the most relevant targets for cancer immunotherapies immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company leading the development of advanced immunotherapies that are active against cancer, today announces that it has...

2014-07-15 14:06:51

University of Texas M. D. Anderson Cancer Center Wide variations seen in up-front therapy versus active surveillance New research from The University of Texas MD Anderson Cancer Center is shedding light on the important role a diagnosing urologist plays in whether older men with low-risk prostate cancer receive treatment for their disease, and if so, the type of treatment they receive as a result. The findings, published in JAMA Internal Medicine, sought to examine why active...

2014-07-14 08:26:37

SAN ANTONIO, July 14, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces that Kareg Corporation's Director of Research, Sheldon S. Traube, has issued the following research report on the company. Sheldon S. Traube, Director of Research, Kareg Corporation, Initiating Coverage with a Speculative Buy Recommendation Read the full report: http://www.genspera.com/press/140711_Genspera_research_report_July2014.pdf...

2014-07-11 09:19:30

Harvard School of Public Health Vasectomy was associated with a small increased risk of prostate cancer, and a stronger risk for advanced or lethal prostate cancer according to a new study from Harvard School of Public Health (HSPH). The researchers found that the association remained even among men who received regular PSA screening, suggesting the increased risk of lethal cancer cannot be explained by diagnostic bias. It is the largest and most comprehensive study to date to look at the...

2014-07-10 08:27:12

Patient was previously enrolled in Can-Fite's Phase I/II liver cancer study and has survived for about 5-years using the Company's cancer drug; The global liver cancer drug market is expected to exceed $2 billion by 2015 PETACH TIKVA, Israel, July 10, 2014 /PRNewswire/ -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that the Israeli...

2014-07-10 08:26:11

Tenacious Lung Cancer Survivor Fights for Her Life and the Lives of Others WASHINGTON, July 10, 2014 /PRNewswire-USNewswire/ -- LUNGevity Foundation announces Bonnie J. Addario, a tenacious lung cancer survivor and advocate, as the July LUNGevity Hero for her work in raising awareness of the disease and funds for lifesaving lung cancer research, especially for early detection methods. In late 2003, Bonnie saw her primary care physician and a neurosurgeon about sharp pain on the left side of...

2014-07-09 16:26:00

LONDON, July 9, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Biopsy Devices : Technology and Global Markets https://www.reportbuyer.com/product/2212013/Biopsy-Devices--Technology-and-Global-Markets.html This report provides an in-depth study of the global biopsy devices methods by device, therapautic segments and geographic markets from 2012 through 2018, with five-year CAGR projections from 2013 through 2018. It focuses on vital display technologies...

2014-07-09 08:28:47

LONDON, ON, July 9, 2014 /CNW/ - Focal Healthcare (Focal) was founded as a spin-off company out of the Centre for Imaging Technology Commercialization (CIMTEC). Focal is developing and marketing MRI-Ultrasound Fusion Biopsy and Therapy systems that have strong potential to become the new "gold standard" in prostate care by capitalizing on CIMTEC's unique intellectual property, as well as its extensive technology development and commercialization expertise in the medical imaging field....

2014-07-08 23:14:27

HealthTronics, Inc., a leading provider of integrated urological and interventional radiology products and services, has signed a distribution agreement through its Endocare, Inc. subsidiary with HS Medical, Inc. that expands HealthTronics’ technology portfolio to include a new, targeted ablation solution. Austin, Texas (PRWEB) July 08, 2014 HealthTronics, Inc., a leading provider of integrated urological and interventional radiology products and services, has signed a distribution...


Word of the Day
toccata
  • In music, a work for a keyboard-instrument, like the pianoforte or organ, originally intended to utilize and display varieties of touch: but the term has been extended so as to include many irregular works, similar to the prelude, the fantasia, and the improvisation.
This word is Italian in origin, coming from the feminine past participle of 'toccare,' to touch.
Related